SciSparc

Company Overview

Snapshot

Founded in August 2004, SciSparc operates with 1–10 employees. The company has raised a total of $63.76 million across 12 funding rounds. In October 2025, SciSparc acquired a publicly traded company on the TSXV, to which it transferred its advanced clinical-stage pharmaceutical portfolio.

Business overview

SciSparc is a clinical-stage pharmaceutical company specializing in the development of cannabinoid-based pharmaceuticals. The company focuses on creating and enhancing a portfolio of technologies and assets for central nervous system disorders. Its current drug development programs, utilizing THC and/or non-psychoactive cannabidiol (CBD), include SCI-110 for Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for pain treatment; and SCI-210 for autism spectrum disorder and epilepsy. SciSparc operates within the Health Tech & Life Sciences sector, specifically targeting pharmaceuticals.

Strategic signal

In September 2024, SciSparc received FDA approval to initiate its pivotal Phase IIb clinical trial for a breakthrough Tourette Syndrome treatment. This regulatory milestone is a significant validation of the company's SCI-110 program and signals a critical advancement in bringing its cannabinoid-based therapies to market, potentially opening up substantial commercial opportunities in the neurodevelopmental disorder space.

Company Intelligence Q&A

What is SciSparc's primary focus in drug development?

SciSparc is primarily focused on developing cannabinoid pharmaceuticals for the treatment of central nervous system disorders, including Tourette syndrome, obstructive sleep apnea, Alzheimer's disease, pain, autism spectrum disorder, and epilepsy.

When did SciSparc receive FDA approval for its Tourette Syndrome treatment trial?

SciSparc received FDA approval in September 2024 to initiate its pivotal Phase IIb clinical trial for a breakthrough Tourette Syndrome treatment.

What was a significant corporate development for SciSparc in October 2025?

In October 2025, SciSparc announced the closing of the acquisition of a publicly traded company on the TSXV, to which it transferred its advanced clinical-stage pharmaceutical portfolio.

What was the outcome of the collaboration between SciSparc and Clearmind Medicine in September 2024?

In September 2024, the collaboration between SciSparc and Clearmind Medicine led to the publication of an international patent application for an innovative MDMA-based combination treatment.

What was the purpose of the 1-for-26 reverse share split announced by SciSparc in September 2023?

In September 2023, SciSparc announced the expected implementation of a 1-for-26 reverse share split, a corporate action often undertaken to increase share price and maintain listing compliance.